AngioDynamics' NanoKnife FDA clearance boosts its potential in cancer treatment. Read why ANGO stock is a buy with its growth ...

AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures are ...

Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ETCompany ParticipantsJim Clemmer - President and Chief ...

An announcement from AngioDynamics ( (ANGO) ) is now available.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...

Reports Q2 revenue $73M, consensus $70.93M. “We are very excited about our strong performance during the second quarter, and in particular the ...

AngioDynamics Inc. ANGO) on Wednesday reported a loss of $10.7 million in its fiscal second quarter. On a per-share basis, the Latham, New York-based company said it had a loss of 26 cents.

In August 2024, President Bola Ahmed Tinubu appointed Mr. Michael Hadi Ango as the Acting Executive Chairman of the Federal ...

AngioDynamics Inc (NASDAQ:ANGO) is set to release its Q2 2025 earnings on Jan 8, 2025. The consensus estimate for Q2 2025 ...